Compare ARMOUR Residential REIT, Inc. (ARR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.72 (market cap $2.07B), while Zimmer Biomet Holdings Inc trades at $97.27 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 9× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays the higher dividend (17.28%). Which is the better fit depends on your goals.
| ARR | ZBH | |
|---|---|---|
Market Cap | $2.07B | $18.55B |
Sector | Financials | Health |
52-Week High | $19.12 | $107.71 |
52-Week Low | $14.05 | $79.58 |
Dividend Yield | 17.28% | 0.99% |
Enterprise Value | — | $25.61B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
